Pericardial Histopathology and COVID-19 Seropositivity

This prospective study aims to investigate the association between pericardial histopathologic inflammation grades (acute, chronic, or absent) and COVID-19 seropositivity in adult patients undergoing first-time isolated coronary artery bypass grafting (CABG). Pericardial tissue samples were collected during surgery and evaluated histopathologically, while preoperative COVID-19 serological testing was performed. The primary outcome is to determine whether COVID-19 seropositivity is associated with the severity of pericardial inflammation. Patients with prior cardiac surgery, active COVID-19 infection, systemic inflammatory diseases, chronic immunosuppressive therapy, or malignancy were excluded from the study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Inflammatory Response COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pericardial Disease Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

20 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Samsun University Faculty of Medicine

Samsun, 55090, Turkey (Türkiye)

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥20 years
Undergoing first-time isolated coronary artery bypass grafting (CABG)
Availability of pericardial tissue sample for histopathological analysis
Preoperative COVID-19 serological testing performed
Written informed consent obtained

Exclusion criteria

Previous history of cardiac surgery (e.g., prior CABG, valve surgery)
Concomitant cardiac procedures during the same operation (e.g., valve repair, aortic surgery)
Active COVID-19 infection at the time of surgery (positive PCR test)
Known autoimmune or systemic inflammatory diseases (e.g., lupus, rheumatoid arthritis)
Chronic immunosuppressive therapy (e.g., steroids, biologics)
Known malignancy at the time of surgery

Insufficient or inadequate pericardial tissue sample for histopathological assessment

Treatment and study plan

Primary outcomes

Pericardial inflammation histopatalogical evaluation

Time frame: up to 1 year

prospective evaluation of the relationship between pericardial inflammation grade (0: absent, 1: mild, 2: moderate, 3: severe) and COVID-19 seropositivity in adult patients undergoing first-time coronary artery bypass grafting. The primary outcome of this study is to investigate the association between pericardial inflammation grade, as determined by histopathological evaluation (categorized as acute, chronic, or absent inflammation), and COVID-19 seropositivity in adult patients undergoing first-time coronary artery bypass grafting.

Sponsors and collaborators

Lead sponsor

Samsun University

Other

Registry information

Official study title

Pericardial Histopathology and COVID-19 Seropositivity in Adult Patients Undergoing First-Time Coronary Artery Bypass Grafting: A Prospective Study

Important dates

Study start: 2023
Primary completion: 2024
Study completion: 2024
First posted: Apr 30, 2025
Registry last updated: Apr 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed